Cargando…

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study

Oligodendrogliomas are defined by mutation in isocitrate dehydrogenase (NADP(+)) (IDH)1/2 genes and chromosome 1p/19q codeletion. World Health Organisation diagnosis endorses testing for 1p/19q codeletion to distinguish IDH mutant (Mut) oligodendrogliomas from astrocytomas because these gliomas requ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habiba, Umma, Sugino, Hirokazu, Yordanova, Roumyana, Ise, Koki, Tanei, Zen-ichi, Ishida, Yusuke, Tanikawa, Satoshi, Terasaka, Shunsuke, Sato, Ken-ichi, Kamoshima, Yuuta, Katoh, Masahiko, Nagane, Motoo, Shibahara, Junji, Tsuda, Masumi, Tanaka, Shinya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138926/ https://www.ncbi.nlm.nih.gov/pubmed/34020723 http://dx.doi.org/10.1186/s40478-021-01194-7

Ejemplares similares

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas
por: Gilhodes, Julia, et al.
Publicado: (2023)

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
por: Lee, Julieann, et al.
Publicado: (2018)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review
por: Shimizu, Hiroyuki, et al.
Publicado: (2020)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
por: Pesenti, Chiara, et al.
Publicado: (2017)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report
por: Agopyan-Miu, Alexander H. C. W., et al.
Publicado: (2021)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1
por: Klink, Barbara, et al.
Publicado: (2013)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

PATH-05. A CASE OF PILOCYTIC ASTROCYTOMA HARBORING THE FGFR1 GENE MUTATION WITH A PREDOMINANT OLIGODENDROGLIOMA-LIKE COMPONENT
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Correction: A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1
por: Klink, Barbara, et al.
Publicado: (2013)

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
por: Ducray, François, et al.
Publicado: (2008)

MPC-8 Serum anti-zinc finger FYVE domain-containing protein 21 (ZFYVE21) autoantibody as a novel biomarker for oligodendroglioma IDH-mutant and 1p/19q co-deletion
por: Matsutani, Tomoo, et al.
Publicado: (2021)

The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations
por: Siakallis, Loizos, et al.
Publicado: (2023)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG
por: Navis, Anna C, et al.
Publicado: (2013)

Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma
por: Ma, Sirui, et al.
Publicado: (2021)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
por: Zhu, Zheng, et al.
Publicado: (2020)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
por: Kim, Gi Jeong, et al.
Publicado: (2023)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dgg7cr097aa6ovd94okdk9mns5